Debt-to-equity in % of AVADEL PHARMACEUTICALS PLC from Q3 2016 to Q3 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
AVADEL PHARMACEUTICALS PLC quarterly Debt-to-equity history and change rate from Q3 2016 to Q3 2025.
  • AVADEL PHARMACEUTICALS PLC Debt-to-equity for the quarter ending 30 Sep 2025 was 113 %, a 4.57% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

AVADEL PHARMACEUTICALS PLC Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 113 +4.95 +4.57% 30 Sep 2025
Q2 2025 116 +16.3 +16.3% 30 Jun 2025
Q1 2025 121 +45.6 +60.3% 31 Mar 2025
Q4 2024 118 -16.2 -12.1% 31 Dec 2024
Q3 2024 108 -141 -56.5% 30 Sep 2024
Q2 2024 100 -668 -87% 30 Jun 2024
Q1 2024 75.6 +944 31 Mar 2024
Q4 2023 134 -3.36K -96.2% 31 Dec 2023
Q3 2023 249 -307 -55.2% 30 Sep 2023
Q2 2023 768 +480 +166% 30 Jun 2023
Q1 2023 -869 -1.06K -560% 31 Mar 2023
Q4 2022 3.49K +3.34K +2208% 31 Dec 2022
Q3 2022 556 +433 +353% 30 Sep 2022
Q2 2022 289 +182 +172% 30 Jun 2022
Q1 2022 189 +93.6 +98.2% 31 Mar 2022
Q4 2021 151 +34.3 +29.3% 31 Dec 2021
Q3 2021 123 -65.8 -34.9% 30 Sep 2021
Q2 2021 106 -336 -75.9% 30 Jun 2021
Q1 2021 95.3 +1.82K 31 Mar 2021
Q4 2020 117 +991 31 Dec 2020
Q3 2020 189 +1.62K 30 Sep 2020
Q2 2020 442 -1.4K -76% 30 Jun 2020
Q1 2020 -1.73K -2.3K -400% 31 Mar 2020
Q4 2019 -874 -1.25K -334% 31 Dec 2019
Q3 2019 -1.43K -1.7K -631% 30 Sep 2019
Q2 2019 1.84K +1.6K +670% 30 Jun 2019
Q1 2019 575 +345 +150% 31 Mar 2019
Q4 2018 373 +143 +62.4% 31 Dec 2018
Q3 2018 269 -10 -3.59% 30 Sep 2018
Q2 2018 239 -132 -35.6% 30 Jun 2018
Q1 2018 230 -197 -46.1% 31 Mar 2018
Q4 2017 230 -168 -42.2% 31 Dec 2017
Q3 2017 279 -46 -14.1% 30 Sep 2017
Q2 2017 371 30 Jun 2017
Q1 2017 428 31 Mar 2017
Q4 2016 398 31 Dec 2016
Q3 2016 325 30 Sep 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.